Treatment with enzyme replacement therapy [MISCELLANEOUS] MPS1 types are distinguished clinically by age of onset and progression or by mutation(s) [MISCELLANEOUS] Alpha-L-iduronidase activity is <1% for all forms of MPS1 [MISCELLANEOUS] Onset of symptoms between ages 3-8 years of age [MISCELLANEOUS] Caused by mutation in the alpha-L-iduronidase gene (IDUA, 252800.0012) [MOLECULAR BASIS]
|